Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 08 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA

Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA, reports the latest issue of the Alimentary Pharmacology & Therapeutics.

News image

Entecavir and tenofovir disoproxil fumarate are the two first-line anti-viral therapies for chronic hepatitis B (CHB).

However, there are limited studies directly comparing their effectiveness.

Dr Nguyen and colleagues from California, USA compared the effectiveness of entecavir and tenofovir in nucleos(t)ide-naïve CHB patients with high hepatitis B virus (HBV) DNA levels, defined as serum HBV DNA greater than 6 log10 IU/mL.

The research team performed a retrospective multicentre cohort study of adult CHB patients who were seen between 2009 and 2012 at 4 Northern California community gastroenterology and hepatology clinics.

The team identified 59 consecutive patients treated with tenofovir and 216 patients treated with entecavir.

Complete suppression was 18% at 6 months with TDF
Alimentary Pharmacology & Therapeutics

Pre-treatment characteristics were similar between the 2 groups.

Among HBeAg-negative patients, there was no significant difference in viral suppression rates between entecavir and tenofovir.

In contrast, among HBeAg-positive patients, those treated with tenofovir achieved viral suppression significantly more rapidly than those treated with entecavir.

The Kaplan–Meier estimated probability of complete suppression was 18% vs. 11% at 6 months, 51% vs. 28% at 12 months and 72% vs 39% at 18 months, with tenofovir and entecavir, respectively.

Multivariate Cox proportional hazards analysis indicated that treatment with tenofovir compared to entecavir was a significant predictor of viral suppression, but only for HBeAg-positive patients.

Dr Nguyen's team concludes, "Tenofovir is significantly more effective than entecavir for achieving complete viral suppression in HBeAg-positive, nucleos(t)ide-naïve chronic hepatitis B patients with HBV DNA greater than 6 log10 IU/mL."

Aliment Pharmacol Ther 2014: 39(6): 629–637
05 March 2014

Go to top of page Email this page Email this page to a colleague

 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Preterm birth in women with IBD
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 29 November 2016 
Treating Zenker's diverticulum
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us